MHRA grants Promising Innovative Medicine designation to Camallergy’s peanut allergy treatment
CAMBRIDGE, UK – 4 April 2024 – Camallergy, a pioneer in developing oral immunotherapy treatments for food allergies, announces it has received a Promising Innovative Medicine (PIM) designation from the UK Medicines and Healthcare products Regulatory Agency (MHRA).
The Promising Innovative Medicine Designation confirms MHRA’s opinion that Camallergy’s medical device enabled treatment for peanut allergy meets each of their three criteria:
Peanut allergy is a serious, life-threatening condition, and there is a high unmet need as there is no method of treatment available or existing methods have serious limitations
Camallergy’s treatment is likely to offer major advantage over the current methods used in the UK
The benefits of Camallergy’s treatment are likely to outweigh the potential adverse effects
A Promising Innovative Medicine Designation is an early indication that a medicinal product is a promising candidate for the Early Access to Medicines Scheme (EAMS), in the treatment, diagnosis or prevention of life-threatening or seriously debilitating conditions with unmet need. It also brings the opportunity to have early in-depth discussions with both the National Health Service (NHS) and the UK’s health technology agencies.
About Camallergy
Camallergy (Cambridge Allergy Ltd) is a biopharmaceutical company spun out from Cambridge University Hospitals NHS Foundation Trust in Cambridge, UK. The company develops innovative, patient-centric treatments based on oral immunotherapy to address the tens of millions of patients worldwide living with food allergies.
Disclaimer
The safety and efficacy of the Camallergy’s treatments are subject to confirmation in Phase 3 clinical trials. They are investigational and not yet approved by regulatory agencies.